Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 414 | 51 | 356 |
| Samples | 203 | 31 | 169 |
| Peptides | 175 | 22 | 156 |
Function
ANXA7 · Annexin A7
Annexin VII is a member of the annexin family of calcium-dependent phospholipid binding proteins.The Annexin VII gene contains 14 exons and spans approximately 34 kb of DNA. An alternatively spliced cassette exon results in two mRNA transcripts of 2.0 and 2.4 kb which are predicted to generate two protein isoforms differing in their N-terminal domain. The alternative splicing event is tissue specific and the mRNA containing the cassette exon is prevalent in brain, heart and skeletal muscle. The transcripts also differ in their 3'-non coding regions by the use of two alternative poly(A) signals. Annexin VII encodes a protein with a molecular weight of approximately 51 kDa with a unique, highly hydrophobic N-terminal domain of 167 amino acids and a conserved C-terminal region of 299 amino acids. The latter domain is composed of alternating hydrophobic and hydrophilic segments. Structural analysis of the protein suggests that Annexin VII is a membrane binding protein with diverse properties, including voltage-sensitive calcium channel activity, ion selectivity and membrane fusion. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 159 amino-acid changes on canonical ENST00000372921 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in ANXA7 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in ANXA7 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 4/40 10% | 0/0 0% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Hodgkins Lymphoma | 2/16 12% | 2/122 2% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 3/133 2% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Endometrial Carcinoma | 0/42 0% | 12/612 2% |
| Melanoma | 0/210 0% | 26/1899 1% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Other Solid Cancers | 1/94 1% | 13/1515 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 6/810 1% |
| Cervical Carcinoma | 2/35 6% | 1/422 0% |
| Colorectal Carcinoma | 4/143 3% | 17/3239 1% |
| Non-Small Cell Lung Carcinoma | 4/304 1% | 5/1390 0% |
| Esophageal Carcinoma | 0/23 0% | 4/769 1% |
| Bladder Carcinoma | 0/58 0% | 5/956 1% |
| Glioma | 0/52 0% | 10/2127 0% |
| Hepatocellular Carcinoma | 1/46 2% | 9/2210 0% |
| Burkitts Lymphoma | 0/32 0% | 1/196 1% |
| Other Sarcomas | 2/69 3% | 1/699 0% |
| Head and Neck Carcinoma | 0/85 0% | 6/1574 0% |
| Gastric Carcinoma | 0/74 0% | 6/1809 0% |
| Ewings Sarcoma | 0/63 0% | 1/262 0% |
| Pancreatic Carcinoma | 2/89 2% | 3/1611 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 7/2550 0% |
| Ovarian Carcinoma | 0/109 0% | 3/998 0% |
| Neuroendocrine Tumour | 2/154 1% | 0/577 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 2/752 0% |
| Prostate Carcinoma | 0/13 0% | 5/2105 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 4/1592 0% |
| Breast Carcinoma | 0/144 0% | 8/3264 0% |
Mutation Distribution
Where ANXA7 is mutated · all tissues, split by cell line vs tissue
How many mutations in ANXA7 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 414 mutations in ANXA7
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|